{Reference Type}: Journal Article
{Title}: Serum biomarkers in patients with drug-resistant epilepsy: a proteomics-based analysis.
{Author}: Ma M;Cheng Y;Hou X;Li Z;Wang M;Ma B;Cheng Q;Ding Z;Feng H;
{Journal}: Front Neurol
{Volume}: 15
{Issue}: 0
{Year}: 2024
{Factor}: 4.086
{DOI}: 10.3389/fneur.2024.1383023
{Abstract}: UNASSIGNED: To investigate the serum biomarkers in patients with drug-resistant epilepsy (DRE).
UNASSIGNED: A total of 9 DRE patients and 9 controls were enrolled. Serum from DRE patients was prospectively collected and analyzed for potential serum biomarkers using TMT18-labeled proteomics. After fine quality control, bioinformatics analysis was conducted to find differentially expressed proteins. Pathway enrichment analysis identified some biological features shared by differential proteins. Protein-protein interaction (PPI) network analysis was further performed to discover the core proteins.
UNASSIGNED: A total of 117 serum differential proteins were found in our study, of which 44 were revised upwards and 73 downwards. The up-regulated proteins mainly include UGGT2, PDIA4, SEMG1, KIAA1191, CCT7 etc. and the down-regulated proteins mainly include ROR1, NIF3L1, ITIH4, CFP, COL11A2 etc. Pathway enrichment analysis identified that the upregulated proteins were mainly enriched in processes such as immune response, extracellular exosome, serine-type endopeptidase activity and complement and coagulation cascades, and the down-regulated proteins were enriched in signal transduction, extracellular exosome, zinc/calcium ion binding and metabolic pathways. PPI network analysis revealed that the core proteins nodes include PRDX6, CAT, PRDX2, SOD1, PARK7, GSR, TXN, ANXA1, HINT1, and S100A8 etc.
UNASSIGNED: The discovery of these differential proteins enriched our understanding of serum biomarkers in patients with DRE and potentially provides guidance for future targeted therapy.